SPORCON LIFESCIENCE ADVISORS ApS

CVR36070358

Core data

Name
SPORCON LIFESCIENCE ADVISORS ApS
Address
Taarbæk Strandvej 108A, 2930, Klampenborg
Founded
Aug 1, 2014
1 / 0.09Jan 2024
Locations (P-units)
1View locations
Branch
Virksomhedsrådgivning og anden ledelsesrådgivning (702000)

Keep track of SPORCON LIFESCIENCE ADVISORS ApS

Get an email when we detect changes to financial reports, ownership or management. Save yourself checking the company again.
Free account

Description

Selskabets formål er at udøve virksomhed med rådgivning, handel og investering samt aktiviteter i tilknytning hertil.

Financials

Company financials
Reporting period
2025DKK
Gross profit
30,956
Operating profit
15,554
Profit before tax
19,112
Net income
16,033
Total assets
5,931,944
Equity
5,851,216
Avg. employees
0
2017–2025

Unlock financial history

Datapublica Risk Score

Locked
Assesses the risk of financial distress using the company’s accounts, history, and connections.
Company score
0 · Low100 · High

What goes into the assessment

  • Financials

  • Accounts and history

  • Owners and management

  • Company and connections

Standard: Score and risk bandPro: Also a detailed explanation of the factors

Contact

From cvr.dk

Company
**@sporcon.dkShow full

Gazelle

Loading gazelle status…

Børsen Gazelle is Dagbladet Børsen's award. Datapublica is not affiliated with Børsen. Calculated statuses are Datapublica's own analysis of public CVR financial-statement data.

Founders

FounderRegistered as founderCurrent rolesOwnership
Ulrik SporkRegistered as founderAug 1, 2014Current roles
Management
Ownership
100 %Legal

People

Ulrik SporkRoles
ManagementEJERREGISTER
TitlesADM. DIR.

Auditor

No auditor data available

Ownership100 %Voting rights100 %FromAug 1, 2014

Child companies

Ownership25–33.32 %Voting rights25 %FromDec 31, 2023
Ownership10–14.99 %Voting rights10 %FromMay 10, 2020
Ownership5–9.99 %Voting rights5 %FromApr 1, 2026

Ultimate owners

Ulrik Spork
Ownership through
Direct
100 %

Indirectly owned companies

Calculated through shown level 2–3 paths
ROS Therapeutics ApS
5–10 %